Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients
George Mathioudakis(Fred Hutch Cancer Center), Richard A. Nash(Colorado Blood Cancer Institute), Mary E.D. Flowers(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ted Gooley(Fred Hutch Cancer Center), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Peter M. Lansdorp(BC Cancer Agency), Jan Storek(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter A. McSweeney(Mesoblast (United States)), Beverly Torok‐Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Eileen Bryant(Leipzig University), M. John Gass(Fred Hutch Cancer Center)
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k